Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,863Revenue (TTM) $M253Net Margin (%)41.1Altman Z-Score14.3
Enterprise Value $M1,772EPS (TTM) $2.0Operating Margin %31.3Piotroski F-Score5
P/E(ttm)18.6Beneish M-Score-1.8Pre-tax Margin (%)30.6Higher ROA y-yY
Price/Book8.110-y EBITDA Growth Rate %--Quick Ratio1.7Cash flow > EarningsN
Price/Sales7.65-y EBITDA Growth Rate %--Current Ratio1.9Lower Leverage y-yY
Price/Free Cash Flow21.2y-y EBITDA Growth Rate %143ROA % (ttm)35.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)55.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M50.7ROIC % (ttm)97.0Gross Margin Increase y-yN

Gurus Latest Trades with SUPN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SUPN is held by these investors:



SUPN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PATRICK GREGORY SVP, CFO 2017-09-08Sell50,000$47.6-22.79view
Bhatt Padmanabh P.Sr VP of IP, CSO 2017-09-08Sell5,000$49.86-26.29view
Schwabe Stefan K.F.Executive Vice President R&D 2017-09-07Sell95,000$46.59-21.12view
Bhatt Padmanabh P.Sr.VP of IP, CSO 2017-08-16Sell3,709$45.23-18.75view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2017-07-12Sell3,735$44.9-18.15view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2017-06-23Sell2,556$44.9-18.15view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2017-06-02Sell10,000$39.86-7.8view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2017-05-26Sell2,500$35.92.37view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2017-05-25Sell5,500$34.95.3view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2017-04-24Sell11,806$32.5912.76view

Press Releases about SUPN :

Quarterly/Annual Reports about SUPN:

News about SUPN:

Articles On GuruFocus.com
Supernus Defeats Second Generic Challenger to Oxtellar XR® Aug 15 2017 
Supernus to Host Second Quarter 2017 Earnings Conference Call Jul 19 2017 
Supernus Announces that its Partner Shire Receives FDA Approval for Mydayis™ for ADHD Jun 21 2017 
Supernus to Present at Jefferies Healthcare Conference Jun 01 2017 
Supernus to Host First Quarter 2017 Earnings Conference Call Apr 26 2017 
Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adol Apr 05 2017 
Supernus Announces Settlement with Actavis on Trokendi XR® Patent Litigation Mar 07 2017 
Supernus Announces Settlement with Zydus on Trokendi XR® Patent Litigation Mar 06 2017 
Robert Bruce new Buys Feb 16 2015 
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 

More From Other Websites
Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SUPN-US :... Sep 20 2017
Today's Research Reports on Stocks to Watch: Capricor Therapeutics and Supernus Pharmaceuticals Sep 20 2017
Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today Sep 19 2017
Supernus Drops SPN-810's Lower Dose Test in Phase III Trials Sep 19 2017
MediWound Shares Lower After Pricing Stock Offering - Biotech Movers Sep 19 2017
Supernus shares decline on drug study change Sep 18 2017
Supernus Provides Update on SPN-810 Phase III Clinical Trials Sep 18 2017
See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc. Sep 11 2017
These 4 Biotechs Just Moved Into Buy Zones; Is This Giant Next? Sep 01 2017
Supernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : August 15, 2017 Aug 15 2017
Supernus Defeats Second Generic Challenger to Oxtellar XR® Aug 15 2017
Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US :... Aug 15 2017
Edited Transcript of SUPN earnings conference call or presentation 3-Aug-17 1:00pm GMT Aug 13 2017
Investor Network: Supernus Pharmaceuticals, Inc. to Host Earnings Call Aug 03 2017
Supernus tops Street 2Q forecasts Aug 02 2017
Supernus Announces Record Second Quarter 2017 Financial Results Aug 02 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}